Experienced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)

Dr. Joseph E. Sullivan

Pediatric Neurology | Neurology
400 Parnassus Ave Fl 8, Box 0348, 
San Francisco, CA 
Experienced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
400 Parnassus Ave Fl 8, Box 0348, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Sullivan is a Pediatric Neurologist and a Neurologist in San Francisco, California. Dr. Sullivan is rated as an Experienced provider by MediFind in the treatment of Genetic Epilepsy with Febrile Seizures Plus (GEFS+). His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, and Epilepsy.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Genetic Epilepsy with Febrile Seizures Plus (GEFS+).

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 12 Less Insurance Carriers -

Locations

400 Parnassus Ave Fl 8, Box 0348, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
Enrollment Status: Terminated
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drug: JBPOS0101
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drug: ZX008 (Fenfluramine Hydrochloride)
Study Phase: Phase 3
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Ganaxolone
Study Phase: Phase 2
View 5 Less Clinical Trials

97 Total Publications

Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers.
Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers.
Journal: Epilepsy & behavior : E&B
Published: July 18, 2025
Similar Doctors
Elite in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. William B. Gallentine
Pediatric Neurology | Neurology | Pediatrics
Elite in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. William B. Gallentine
Pediatric Neurology | Neurology | Pediatrics
750 Welch Rd, 
Palo Alto, CA 
 (27.3 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

William Gallentine is a Pediatric Neurologist and a Neurologist in Palo Alto, California. Dr. Gallentine is rated as a Distinguished provider by MediFind in the treatment of Genetic Epilepsy with Febrile Seizures Plus (GEFS+). His top areas of expertise are Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Seizures, Status Epilepticus, and Absence Seizure.

Advanced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. Emily M. Spelbrink
Pediatric Neurology | Neurology
Advanced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. Emily M. Spelbrink
Pediatric Neurology | Neurology
725 Welch Rd, 
Palo Alto, CA 
 (27.5 miles away)
650-736-0885
Languages Spoken:
English
See accepted insurances

Emily Spelbrink is a Pediatric Neurologist and a Neurologist in Palo Alto, California. Dr. Spelbrink is rated as a Distinguished provider by MediFind in the treatment of Genetic Epilepsy with Febrile Seizures Plus (GEFS+). Her top areas of expertise are West Syndrome, Seizures, Myoclonic Epilepsy, and Genetic Epilepsy with Febrile Seizures Plus (GEFS+).

Advanced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. Dawn C. Duane
Pediatric Neurology | Neurology
Advanced in Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Dr. Dawn C. Duane
Pediatric Neurology | Neurology
725 Welch Rd, 
Palo Alto, CA 
 (27.5 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Dawn Duane is a Pediatric Neurologist and a Neurologist in Palo Alto, California. Dr. Duane is rated as an Advanced provider by MediFind in the treatment of Genetic Epilepsy with Febrile Seizures Plus (GEFS+). Her top areas of expertise are Zika Virus Disease, Microcephaly with Spastic Quadriplegia, Microcephaly, and Infant Botulism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sullivan's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile